Connect with us

Biotech

Diversa Finalizes its Market Launch With an Eye on the US, Europe, and Japan

Diversa’s patented technology is based on lipid emulsions with an “easily controllable size and narrow distribution”. These nanometer emulsions can associate a wide variety of compounds and show high association efficiency, allowing them to be delivered to their target site overcoming biological barriers. The company has already raised $231,000 (€200,000) from business angels.

Published

on

After opening a seed financing round of $347,000 (€300,000), the Galician startup Diversa has reached agreements with a distributor, whose name has not been disclosed, to market its technology in the United States, Europe, and Japan, according to María de la Fuente, founder, and CEO of the company.

This Galician startup has developed its own technology based on chemical emulsions. The aim of these compounds is to act as new vehicles capable of favoring the release of biomolecules and drugs in targets that are difficult to access on an intracellular scale.

In this sense, Diversa is oriented towards the design of solutions to unresolved medical needs, so “advanced chemical formulations are needed to overcome the body’s own barriers,” explained De la Fuente. The solutions produced by the company “aim to support the production of more efficient pharmaceutical products,” adds the founder.

If you want to read more about the biotech comp[any Diversa and its plans to expand to the US, Europe, and Japan, download fro free our companion app. The Born2Invest mobile app brings you the latest financial news in the world so you can stay informed.

Diversa has already raised $231,000 (€200,000) from business angels, and expects to close the round before the new year

Diversa’s patented technology is based on lipid emulsions with an “easily controllable size and narrow distribution”. These nanometer emulsions can associate a wide variety of compounds and show high association efficiency, allowing them to be delivered to their target site overcoming biological barriers.

Diversa organizes its business offer in three differentiated lines. The first is aimed at supplying independent researchers and is based on the commercialization of its vehicle through kits, at a price of $579 (€500) per unit.

SEE ALSO  Prices of US wheat weaken while Canada's wheat stocks remain strong

The second focuses on customized development for pharmaceutical companies to work on solutions to unresolved medical needs. In this sense, the company already has companies such as 4basebio and ZeClínics as clients. Finally, Diversa also focuses on providing services through research centers.

The company has already raised $231,000 (€200,000) from business angels and expects to close the round before the new year, so the launch of the reagents is prepared for early January 2021. Diversa currently has a team of ten employees made up of clinicians, pharmacists, biologists, and chemists.

Diversa was created this year as a biotechnological spin-off of the Nano-oncology and Translational Therapeutics Unit of the Health Research Institute of Santiago de Compostela (Idis) and the Galician Health Service (Sergas) and is based at the University Campus of Santiago de Compostela.

__

(Featured image by nattanan23 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.